Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal

Yosuke Togashi, Hidetoshi Hayashi, Kunio Okamoto, Soichi Fumita, Masato Terashima, Marco A. de Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Kazuhiko Nakagawa, Kazuto Nishio

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Some of patients with non-small cell lung cancer (NSCLC) harboring somatic activating mutations of the epidermal growth factor receptor gene (. EGFR mutations) show poor responses to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment. Cigarette smoking is the strongest documented risk factor for the development of lung cancer. Nicotine, while not carcinogenic by itself, has been shown to induce proliferation, angiogenesis, and the epithelial-mesenchymal transition; these effects might be associated with EGFR-TKI resistance. Materials and methods: PC-9 and 11_18 cell lines (. EGFR-mutated NSCLC cell lines) were cultured with 1. μM nicotine for 3 months and were designated as PC-9/N and 11_18/N cell lines, respectively. The sensitivities of these cell lines to EGFR-TKI were then tested in vitro. Moreover, the association between the smoking status and the progression-free survival (PFS) period was investigated in patients with EGFR-mutated NSCLC who were treated with gefitinib. Results: The PC-9/N and 11_18/N cell lines were resistant to EGFR-TKI, compared with controls. The phosphorylation of EGFR in these cell lines was reduced by EGFR-TKI to a smaller extent than that observed in controls, and a higher concentration of EGFR-TKI was capable of further decreasing the phosphorylation. Clinically, smoking history was an independent predictor of a poor PFS period on gefitinib treatment. Conclusions: Chronic nicotine exposure because of cigarette smoking mediates resistance to EGFR-TKI via an EGFR signal. Smoking cessation is of great importance, while resistance may be overcome through the administration of high-dose EGFR-TKI.

Original languageEnglish
Pages (from-to)16-23
Number of pages8
JournalLung Cancer
Volume88
Issue number1
DOIs
Publication statusPublished - Apr 1 2015
Externally publishedYes

Fingerprint

Nicotine
Protein-Tyrosine Kinases
Lung Neoplasms
Cell Line
Smoking
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Phosphorylation
erbB-1 Genes
Mutation
Epithelial-Mesenchymal Transition
Smoking Cessation
History
Therapeutics

Keywords

  • Cigarette smoking
  • Epidermal growth factor receptor mutation
  • Epidermal growth factor receptor tyrosine kinase inhibitor
  • Nicotine
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Medicine(all)

Cite this

Togashi, Y., Hayashi, H., Okamoto, K., Fumita, S., Terashima, M., de Velasco, M. A., ... Nishio, K. (2015). Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. Lung Cancer, 88(1), 16-23. https://doi.org/10.1016/j.lungcan.2015.01.027

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. / Togashi, Yosuke; Hayashi, Hidetoshi; Okamoto, Kunio; Fumita, Soichi; Terashima, Masato; de Velasco, Marco A.; Sakai, Kazuko; Fujita, Yoshihiko; Tomida, Shuta; Nakagawa, Kazuhiko; Nishio, Kazuto.

In: Lung Cancer, Vol. 88, No. 1, 01.04.2015, p. 16-23.

Research output: Contribution to journalArticle

Togashi, Y, Hayashi, H, Okamoto, K, Fumita, S, Terashima, M, de Velasco, MA, Sakai, K, Fujita, Y, Tomida, S, Nakagawa, K & Nishio, K 2015, 'Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal', Lung Cancer, vol. 88, no. 1, pp. 16-23. https://doi.org/10.1016/j.lungcan.2015.01.027
Togashi, Yosuke ; Hayashi, Hidetoshi ; Okamoto, Kunio ; Fumita, Soichi ; Terashima, Masato ; de Velasco, Marco A. ; Sakai, Kazuko ; Fujita, Yoshihiko ; Tomida, Shuta ; Nakagawa, Kazuhiko ; Nishio, Kazuto. / Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. In: Lung Cancer. 2015 ; Vol. 88, No. 1. pp. 16-23.
@article{ce6893d43370450c9d4ea643ef508637,
title = "Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal",
abstract = "Background: Some of patients with non-small cell lung cancer (NSCLC) harboring somatic activating mutations of the epidermal growth factor receptor gene (. EGFR mutations) show poor responses to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment. Cigarette smoking is the strongest documented risk factor for the development of lung cancer. Nicotine, while not carcinogenic by itself, has been shown to induce proliferation, angiogenesis, and the epithelial-mesenchymal transition; these effects might be associated with EGFR-TKI resistance. Materials and methods: PC-9 and 11_18 cell lines (. EGFR-mutated NSCLC cell lines) were cultured with 1. μM nicotine for 3 months and were designated as PC-9/N and 11_18/N cell lines, respectively. The sensitivities of these cell lines to EGFR-TKI were then tested in vitro. Moreover, the association between the smoking status and the progression-free survival (PFS) period was investigated in patients with EGFR-mutated NSCLC who were treated with gefitinib. Results: The PC-9/N and 11_18/N cell lines were resistant to EGFR-TKI, compared with controls. The phosphorylation of EGFR in these cell lines was reduced by EGFR-TKI to a smaller extent than that observed in controls, and a higher concentration of EGFR-TKI was capable of further decreasing the phosphorylation. Clinically, smoking history was an independent predictor of a poor PFS period on gefitinib treatment. Conclusions: Chronic nicotine exposure because of cigarette smoking mediates resistance to EGFR-TKI via an EGFR signal. Smoking cessation is of great importance, while resistance may be overcome through the administration of high-dose EGFR-TKI.",
keywords = "Cigarette smoking, Epidermal growth factor receptor mutation, Epidermal growth factor receptor tyrosine kinase inhibitor, Nicotine, Non-small cell lung cancer",
author = "Yosuke Togashi and Hidetoshi Hayashi and Kunio Okamoto and Soichi Fumita and Masato Terashima and {de Velasco}, {Marco A.} and Kazuko Sakai and Yoshihiko Fujita and Shuta Tomida and Kazuhiko Nakagawa and Kazuto Nishio",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.lungcan.2015.01.027",
language = "English",
volume = "88",
pages = "16--23",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal

AU - Togashi, Yosuke

AU - Hayashi, Hidetoshi

AU - Okamoto, Kunio

AU - Fumita, Soichi

AU - Terashima, Masato

AU - de Velasco, Marco A.

AU - Sakai, Kazuko

AU - Fujita, Yoshihiko

AU - Tomida, Shuta

AU - Nakagawa, Kazuhiko

AU - Nishio, Kazuto

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: Some of patients with non-small cell lung cancer (NSCLC) harboring somatic activating mutations of the epidermal growth factor receptor gene (. EGFR mutations) show poor responses to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment. Cigarette smoking is the strongest documented risk factor for the development of lung cancer. Nicotine, while not carcinogenic by itself, has been shown to induce proliferation, angiogenesis, and the epithelial-mesenchymal transition; these effects might be associated with EGFR-TKI resistance. Materials and methods: PC-9 and 11_18 cell lines (. EGFR-mutated NSCLC cell lines) were cultured with 1. μM nicotine for 3 months and were designated as PC-9/N and 11_18/N cell lines, respectively. The sensitivities of these cell lines to EGFR-TKI were then tested in vitro. Moreover, the association between the smoking status and the progression-free survival (PFS) period was investigated in patients with EGFR-mutated NSCLC who were treated with gefitinib. Results: The PC-9/N and 11_18/N cell lines were resistant to EGFR-TKI, compared with controls. The phosphorylation of EGFR in these cell lines was reduced by EGFR-TKI to a smaller extent than that observed in controls, and a higher concentration of EGFR-TKI was capable of further decreasing the phosphorylation. Clinically, smoking history was an independent predictor of a poor PFS period on gefitinib treatment. Conclusions: Chronic nicotine exposure because of cigarette smoking mediates resistance to EGFR-TKI via an EGFR signal. Smoking cessation is of great importance, while resistance may be overcome through the administration of high-dose EGFR-TKI.

AB - Background: Some of patients with non-small cell lung cancer (NSCLC) harboring somatic activating mutations of the epidermal growth factor receptor gene (. EGFR mutations) show poor responses to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment. Cigarette smoking is the strongest documented risk factor for the development of lung cancer. Nicotine, while not carcinogenic by itself, has been shown to induce proliferation, angiogenesis, and the epithelial-mesenchymal transition; these effects might be associated with EGFR-TKI resistance. Materials and methods: PC-9 and 11_18 cell lines (. EGFR-mutated NSCLC cell lines) were cultured with 1. μM nicotine for 3 months and were designated as PC-9/N and 11_18/N cell lines, respectively. The sensitivities of these cell lines to EGFR-TKI were then tested in vitro. Moreover, the association between the smoking status and the progression-free survival (PFS) period was investigated in patients with EGFR-mutated NSCLC who were treated with gefitinib. Results: The PC-9/N and 11_18/N cell lines were resistant to EGFR-TKI, compared with controls. The phosphorylation of EGFR in these cell lines was reduced by EGFR-TKI to a smaller extent than that observed in controls, and a higher concentration of EGFR-TKI was capable of further decreasing the phosphorylation. Clinically, smoking history was an independent predictor of a poor PFS period on gefitinib treatment. Conclusions: Chronic nicotine exposure because of cigarette smoking mediates resistance to EGFR-TKI via an EGFR signal. Smoking cessation is of great importance, while resistance may be overcome through the administration of high-dose EGFR-TKI.

KW - Cigarette smoking

KW - Epidermal growth factor receptor mutation

KW - Epidermal growth factor receptor tyrosine kinase inhibitor

KW - Nicotine

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84924590379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924590379&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.01.027

DO - 10.1016/j.lungcan.2015.01.027

M3 - Article

C2 - 25704955

AN - SCOPUS:84924590379

VL - 88

SP - 16

EP - 23

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -